The UK is set to give a unique second life to used nuclear materials. A £9.9m investment from the Innovate UK Sustainable Medicines Manufacturing Innovation Programme (SMMIP), backed by a further £8.9m from industry, will support a major project to develop cutting-edge new treatments for cancer.
Led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), the project will use a radionuclide called lead-212 to create treatments called Targeted Alpha Therapies.
These treatments are a type of precision medicine, known as radiopharmaceuticals. Whilst…
Venture Partner at Samsara BioCapital, and former CSO and COO of Karus Therapeutics, brings deep scientific and industry experience to Mosaic’s Executive Leadership team
· Stephen will lead the Company’s scientific strategy, preclinical pipeline build and R&D organisation
Cambridge, UK, 17 November 2025: Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced the appointment of Dr Stephen Shuttleworth as Chief Scientific…
Mursla Bio’s AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease
Cambridge, UK, and Boston MA, USA, 13 November 2025: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve chronic disease outcomes for at-risk patients, today announced a collaboration with a leading global pharmaceutical company recognized for its expertise in precision medicine and biomarker-guided drug development.
Under the collaboration, Mursla Bio’s AI Precision Medicine…
· Industry leader brings deep expertise across neurodegenerative disease therapeutics development
· Dr Hutton joins Prof. Alessio Ciulli FRS and Dr Adam Gilbert on SAB
Cambridge, UK, 11 November 2025: TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today announced the appointment of Dr Mike Hutton to its Scientific Advisory Board (SAB). Mike will provide expert guidance to support the development of the…
San Diego, CA & Montpellier, FR – November 6, 2025 – Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on the discovery and development of fully human antibodies, announced the formation of a strategic partnership. This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution.
Understanding the challenges of early-stage development, Mabqi and Abzena formed…
SoluLyse™ from Amsbio is a bacterial protein extraction reagent that provides a highly efficient yet gentle method for extracting soluble proteins from bacterial cells.
Based upon a proprietary non-ionic detergent formulation, with the SoluLyse™ reagent there is no need for time-consuming and cumbersome secondary treatment methods such as sonication or freeze thaw. The unique, mild SoluLyse™ formulation allows perforation of bacterial cell walls without denaturing proteins.
In addition, the SoluLyse™ reagent offers an up to ten-fold increase in the yield of soluble proteins when…
Tony JonesCEO, One Nucleus
The Final CountdownWriting this whilst many of our members and network are exploring opportunities in Vienna with One Nucleus Partner EBD Group, it felt appropriate to start this welcome to our eNews with a song title by Europe from way back in 1986. Bio-partnering may not have been a familiar term back then to most, yet here in 2025 some entrepreneurs, investors and service providers may never have known a sector without it. But now we are in the final countdown to one of the most exciting conference, networking and partnering events of the year – Genesis…
Partnership with Solve Scientific strengthens international sales as part of ongoing global expansion
Cambridge, UK, and Boston MA, USA, 03 November 2025: Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, today announced that it has signed a partnership with Solve Scientific Australia, a life science research solutions provider. The agreement is the latest milestone in Nuclera’s global expansion, broadening access to eProtein Discovery to customers in Australia and New…
LONDON, UK & COPENHAGEN, Denmark – November 4, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Vicore Pharma Holding AB (STO: VICO) and is pleased to announce the placement of Katrine Husum as R&D Senior Project Director.Vicore Pharma is a clinical-stage pharmaceutical company focused on developing treatments for severe respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company is developing a new class of…
The October edition of our People Pathways newsletter is now available to read here!
Featuring:
✅ Preview of One Nucleus 2026 courses
✅ One Nucleus Jobs Board - Helping the Industry
✅ Online Training in Python Programming, Data Science, Networks, Machine Learning & AI
and some useful information...